West Pharmaceutical Services (WST) is seeing a positive outlook with rising analyst price targets and expected Q2 earnings beat due to high demand for biologics and GLP-1 drug components. The company’s stock has climbed nearly 33% year-to-date, reflecting confidence in its market position and improved manufacturing. Analysts expect continued growth in revenue and earnings through 2026, supported by strong demand and operational improvements. The company will release its Q2 2026 results on July 23, which could further influence investor sentiment.
Yesway, Inc. reported a 36% year-over-year revenue increase in Q2 2026, driven mainly by fuel sales, though its GAAP earnings per share fell short of expectations. The company raised its full-year 2026 Adjusted EBITDA guidance to $235 million–$245 mi...
SoFi Technologies reported strong Q2 results with revenue up 42.6% year-over-year to $1.22 billion, driven by rapid innovation and robust membership growth reaching a record 15.81 million. This growth fuels increased product usage per member and new ...
Gunnison Copper Corp has completed its planned metallurgical drilling at the Gunnison deposit in Arizona and expanded its testing program as part of its 2026 district-wide drilling campaign. The company is currently operating two drill rigs and plans...
Optima Health PLC reported adjusted earnings of £20.1 million for the year to March, exceeding broker Cavendish's forecasts by about 12%. The company benefited from a £4.7 million settlement but also showed improved underlying profitability, with sec...
ReconAfrica Energy Africa has successfully flowed natural gas and potential liquids from the second Huttenberg zone at its Kavango West 1X well, completing vertical testing and preparing for a horizontal open-hole test. The flow occurred immediately ...
